OBJECTIVE： To explore the method and effect of clinical pharmacists providing pharmaceutical care for renal massive hemorrhage patient after neuroendovascular stenting. METHODS： Clinical pharmacist participated in the primary antithrombotic treatment protocol evaluation， the cause analysis of hemorrhage and the formulation of antithrombotic treatment protocol of orce patient with renal massive hemorrhage after neuroendovascular stenting. According to the hemorrhage degree of patients， clinical pharmacists judged it was renal massive hemorrhage and correlated to intensified antithrombotic treatment； after receiving left renal artery amgiography+bleeding artery embolization+blood transfusion for twice suggested to stop taking aspirin and clopidogrel； suggested to take Octreotide acetate injection 0.025 mg/h，ivgtt， for stopping bleeding， Esomeprazole sodium for injection 20 mg，ivgtt，qd， for inhibiting acid and preventing stress ulcer， Ceftriaxone sodium for injection 2 g，ivgtt，qd， for anti-infective treatment and Mecobalamine injection 0.5 mg，ivgtt，tiw， for nourishing nerve； the patient received antithrombotic treatment again after renal hemorrhage had been controlled and took Clopidogrel hydrogen sulfate tablet 75 mg，po，qd. RESULTS： Physicians adopted the suggestions of clinical pharmacists. Bleeding was controlled and no embolic events occurred.  CONCLUSIONS： Intensified antithrombotic treatment can reduce embolism events during neuroendovascular stenting but the risk of bleeding is increased. Clinical pharmacists need to assist physicians in formulating rational antithrombotic treatment protocol for patients by balancing the hemorrhage and thrombosis risk.